ReviewCancer management and research2015
Minimizing second cancer risk following radiotherapy: current perspectives.
Review in Cancer management and research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Incidence of second primary cancers in patients with retinoblastoma: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- The Potential of Physical Exercise to Mitigate Radiation Damage-A Systematic Review.Frontiers in medicine · 2021Pooled it
- Comparative Dosimetric Analysis of Jaw Tracking Versus Non-Jaw Tracking Techniques in Head and Neck and Brain Cancers: A Systematic Review and Meta-Analysis.Advanced biomedical research · 2026Review
- Current insights into breast and ovarian cancer risk: a contemporary review.Minerva surgery · 2025Review
- Structural and temporal dynamics analysis on immune response in low-dose radiation: History, research hotspots and emerging trends.World journal of radiology · 2025Article
- Roles of Mesenchymal Stem Cells in Breast Cancer Therapy: Engineered Stem Cells and Exosomal Cell-Free Based Therapy.Current molecular medicine · 2025Review
- Current trends in breast cancer genetics, risk factors, and screening strategies.Journal of biological methods · 2025Review
- Glucocorticoid receptors orchestrate a convergence of host and cellular stress signals in triple negative breast cancer.The Journal of steroid biochemistry and molecular biology · 2024Review
- A data-driven approach to improve wellness and reduce recurrence in cancer survivors.Frontiers in oncology · 2024Article
- Comparison of helical and TomoDirect techniques with simultaneous integrated boost in early breast cancer patients.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2023Article
- Patients with Early-Onset Colorectal Cancer Have an Increased Risk of Second Primary Malignancy.Digestive diseases and sciences · 2022Article
- Age-related long-term response in rat thyroid tissue and plasma after internal low dose exposure toScientific reports · 2022Article
- Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence.Frontiers in molecular biosciences · 2022Review
- Review
- Secondary cancer risk from modern external-beam radiotherapy of prostate cancer patients: Impact of fractionation and dose distribution.Journal of radiation research · 2021Article
- Risk of radiation-induced second malignant neoplasms from photon and proton radiotherapy in paediatric abdominal neuroblastoma.Physics and imaging in radiation oncology · 2021Article
- Out-of-field dose in stereotactic radiotherapy for paediatric patients.Physics and imaging in radiation oncology · 2021Article
- Second primary malignancies after ocular adnexal lymphoma diagnosis.BMC ophthalmology · 2021Article
- Younger North Americans are exposed to more radon gas due to occupancy biases within the residential built environment.Scientific reports · 2021Article
- Auxiliary Structures-Assisted Radiotherapy Improvement for Advanced Left Breast Cancer.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secondary cancer risk following radiotherapy is an increasingly important topic in clinical oncology with impact on treatment decision making and on patient management. Much of the evidence that underlies our understanding of secondary cancer risks and our risk estimates are derived from large epidemiologic studies and predictive models of earlier decades with large uncertainties. The modern era is characterized by more conformal radiotherapy technologies, molecular and genetic marker approaches, genome-wide studies and risk stratifications, and sophisticated biologically based predictive models of the carcinogenesis process. Four key areas that have strong evidence toward affecting secondary cancer risks are 1) the patient age at time of radiation treatment, 2) genetic risk factors, 3) the organ and tissue site receiving radiation, and 4) the dose and volume of tissue being irradiated by a particular radiation technology. This review attempts to summarize our current understanding on the impact on secondary cancer risks for each of these known risk factors. We review the recent advances in genetic studies and carcinogenesis models that are providing insight into the biologic processes that occur from tissue irradiation to the development of a secondary malignancy. Finally, we discuss current approaches toward minimizing the risk of radiation-associated secondary malignancies, an important goal of clinical radiation oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.